Thymic hyperplasia in myasthenia gravis: immunohistological abnormalities and responsiveness to recombinant IL2.
Cohen-Kaminsky
S
S
Centre Chirurgical Marie-Lannelongue, CNRS UA 04-1159, Le Plessis-Robinson, France.
Berrih-Aknin
S
S
Safar
D
D
D000293:Adolescent; D000328:Adult; D004848:Epithelium / Q000473:pathology; D005455:Fluorescent Antibody Technique; D006801:Humans; D006965:Hyperplasia; D007167:Immunotherapy; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000627:therapeutic use; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000473:pathology*; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000473:pathology* / Q000628:therapy; D015375:Receptors, Interleukin-2 / Q000032:analysis; D011994:Recombinant Proteins; D013950:Thymus Gland / Q000473:pathology*
D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins